Pay in 4 interest-free payments of $6.05 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
However, individuals with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) may benefit from periodic monitoring to assess improvements in liver health as weight loss progresses
What it means for you If you have diabetes or obesity and are prescribed a GLP-1 RA anyway, it may be a potential added brain-health benefitbut not a guarantee
Clinical Evidence What the research shows Tirzepatides SURMOUNT trial program produced the most significant weight loss outcomes ever recorded for a pharmaceutical intervention
Semaglutide has been FDA-approved for the treatment of type 2 diabetes (as Ozempic) and obesity (as Wegovy)
Cardiovascular Risk Reduction 2 FDA-approved to reduce the risk of major cardiovascular events (heart attack, stroke, cardiovascular death) in adults with type 2 diabetes and established cardiovascular disease
Journal of Metabolic Syndrome, 12(4), 345-353
